Initial Experience: Alleviation of Pain with Percutaneous CT-Guided Cryoablation for Recurrent Retroperitoneal Soft-Tissue Sarcoma

详细信息    查看全文

• 作者：Wen-Zhe Fan ; MD^a ; Li-Zhi Niu ; MD^d ; ^e ; Yu Wang ; MD^a ; Xue-Hua Yao ; MS^a ; Ying-Qiang Zhang ; MS^a ; Guo-Sheng Tan ; MD^b ; Jian-Yong Yang ; MD^b ; ^c ; Jia-Ping Li ; MD^a ; ^{lijiaping_2011@126.com}
• 关键词：CR ; complete response ; PD ; progressive disease ; PFS ; progression-free survival ; PR ; partial response ; RPS ; retroperitoneal soft-tissue sarcoma ; RR ; response rate ; SD ; stable disease ; VAS ; visual analog scale
• 刊名：Journal of Vascular and Interventional Radiology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：27
• 期：12
• 页码：1798-1805
• 全文大小：1059 K
• 卷排序：27

文摘

To evaluate the pain-alleviating effect of computed tomography (CT)–guided percutaneous cryoablation for recurrent retroperitoneal soft-tissue sarcomas (RPSs).Materials and MethodsData from 19 men and 20 women (median age, 50.3 y) with recurrent malignant RPS who underwent percutaneous cryoablation were reviewed retrospectively. A total of 50 tumors were treated by cryoablation, including a single tumor in 29 patients, 2 tumors in 9, and 3 tumors in 1. Adverse events and analgesic outcomes were compared as a function of tumor size (< 10 cm and ≥ 10 cm). Efficacy was assessed based on modified Response Evaluation Criteria In Solid Tumors and progression-free survival (PFS).ResultsGrade 1/2 adverse events included fever (n = 17), emesis (n = 7), frostbite (n = 5), and local pain (n = 4). The median follow-up period and PFS were 18.5 months (range, 12–42 mo) and 13.4 months ± 6.2, respectively. At the end of follow-up, 13 patients had died and 26 were living. The mean severe local pain scores on pretreatment day 1 and posttreatment days 1, 5, 10, 15, 20, and 25 were 7.49, 7.40, 6.51, 5.81, 5.35, 5.04, and 5.44, respectively, and significant differences versus pretreatment (P < .001) were reported for posttreatment days 5–25. Immediate relief occurred more frequently in the small-tumor group (4 of 7; 57.1%; P = .018), whereas delayed relief occurred more frequently in the large-tumor group (17 of 22; 77.3%; P = .030).ConclusionsMinimally invasive percutaneous cryoablation improves local pain and is a feasible treatment for recurrent RPSs.